Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

MEK Inhibition Reduces Vascular Malformations and Gene Dysregulation in NRASQ61R Human Endothelial Cells.

Pediatric blood & cancer - 1 Mar 2026

Alharbi Sara, Wagner Andrew, Merkle Svatava, Pastura Patricia, McDaniel C Griffin, Fox Dermot, Xu Yan, Le Cras Timothy D

Abstract excerpt

BACKGROUND: An activating NRAS p.Q61R (NRASQ61R) somatic mutation occurs in the lesions of patients with kaposiform lymphangiomatosis (KLA). Therapies for KLA patients are limited and since the mitogen-activated protein kinase pathway is hyperactivated by NRASQ61R, we evaluated the potency of Mitogen-activated protein kinase kinase (MEK) inhibitors (trametinib, selumetinib, and cobimetinib) on human NRASQ61R...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Azetidines
Share to Benzimidazoles

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to GTP Phosphohydrolases

Share to Mitogen-Activated Protein Kinase Kinases

Share to Piperidines

Share to Pyridones

Share to Pyrimidinones

Share to Xenograft Model Antitumor Assays

Source

Open in PubMed Open full text

Identifiers

PMID: 41496696
DOI: 10.1002/1545-5017.70002
PMCID: PMC12782284

Genes

ANG
NRAS
DLL4
HES1
JAG1

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

MEK Inhibition Reduces Vascular Malformations and Gene Dysregulation in NRASQ61R Human Endothelial Cells.PMID 41496696Read ↗

RAS Inhibitor RMC-7977 Blocks Vascular Overgrowth of NRASQ61R Mutant Endothelial Cells.Semantic proximity Read ↗

NRASQ61R mutation drives elevated angiopoietin-2 expression in human endothelial cells and a genetic mouse model.Semantic proximity Read ↗

Life-threatening Lymphatic Malformation With Somatic Activating NRAS Mutation Successfully Treated With Trametinib: A Case StudySemantic proximity Read ↗

Treatment of severe Kaposiform lymphangiomatosis positive for NRAS mutation by MEK inhibition.Semantic proximity Read ↗

Changes in cell morphology and function induced by <i>NRAS</i> Q61R mutation in lymphatic endothelial cellsSemantic proximity Read ↗

A high-throughput zebrafish screen identifies novel candidate treatments for Kaposiform Lymphangiomatosis (KLA)Semantic proximity Read ↗

NRASQ61R mutation in human endothelial cells causes vascular malformations.Semantic proximity Read ↗

Changes in cell morphology and function induced by the NRAS Q61R mutation in lymphatic endothelial cells.Semantic proximity Read ↗

KDR activating mutations in human angiosarcomas are sensitive to specific kinase inhibitors.Semantic proximity Read ↗

Genomic Landscape of Lymphatic Malformations: A Case Series and Response to the PI3Kα Inhibitor Alpelisib in an N-of-One Clinical TrialSemantic proximity Read ↗

Endothelial cell malignancies: new insights from the laboratory and clinicSemantic proximity Read ↗

A Single-cell Atlas of Juvenile Nasopharyngeal Angiofibroma Reveals VEGF-Driven Angiogenic Remodeling as a Therapeutic VulnerabilitySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.